View Older Stories

May 4, 2026 07:29AM H.C. Wainwright Reiterates Buy Rating on Rezolute (RZLT)

Mar 25, 2026 07:02AM Rezolute (RZLT) Reiterated at Neutral by Cantor Fitzgerald After FDA Meeting

Mar 25, 2026 06:58AM H.C. Wainwright Reiterates Buy Rating on Rezolute (RZLT)

Mar 25, 2026 06:37AM Wedbush Upgrades Rezolute (RZLT) to Outperform

Mar 25, 2026 05:33AM Rezolute (RZLT) Reiterated at Market Perform by Citizens on CHI Program Clarity

Mar 24, 2026 03:40PM BTIG sees 'incremental positives' in Rezolute (RZLT) regulatory update

Feb 12, 2026 04:40PM Rezolute, Inc. (RZLT) Misses Q2 EPS by 3c

Jan 26, 2026 05:33AM Rezolute Inc. (RZLT) February 5 calls active

Jan 8, 2026 04:13AM Jefferies Reiterates Buy Rating on Rezolute (RZLT)

Dec 12, 2025 03:00PM RZLT INVESTIGATION: Rezolute, Inc. Investors Should Contact Block & Leviton LLP To Potentially Recover Losses

Dec 12, 2025 09:19AM Craig-Hallum Downgrades Rezolute (RZLT) to Hold

Dec 12, 2025 07:12AM Rezolute (RZLT) PT Lowered to $6 at Guggenheim

Dec 12, 2025 06:43AM Rezolute (RZLT) PT Lowered to $5 at H.C. Wainwright

Dec 11, 2025 12:27PM Rezolute (RZLT) PT Lowered to $5 at BTIG

Dec 11, 2025 11:37AM Cantor Fitzgerald Downgrades Rezolute (RZLT) to Neutral

Dec 11, 2025 10:22AM Wedbush Downgrades Rezolute (RZLT) to Neutral

Nov 12, 2025 07:32AM Rezolute (RZLT) PT Raised to $14 at Jones Trading

Nov 6, 2025 06:24PM Rezolute, Inc. (RZLT) Tops Q1 EPS by 4c

Nov 6, 2025 06:24PM Rezolute, Inc. (RZLT) Tops Q1 EPS by 4c

Oct 29, 2025 04:26AM Rezolute (RZLT) PT Raised to $17 at Citizens After Phase 3 sunRIZE Results

Sep 18, 2025 05:27AM Rezolute (RZLT) PT Raised to $14 at Jefferies

Sep 18, 2025 04:12AM Citizens JMP Reiterates Market Outperform Rating on Rezolute (RZLT)

Sep 3, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Rezolute (RZLT)

Aug 20, 2025 06:14AM Rezolute Inc. (RZLT) Appoints Sunil Karnawat as Chief Commercial Officer

Jul 24, 2025 08:49AM Cantor Fitzgerald Reiterates Overweight Rating on Rezolute (RZLT)

Jul 17, 2025 05:06PM Rezolute Inc. (RZLT) Files for 1.3M Share Offering by Selling Stockholders

May 28, 2025 02:27PM BTIG Reiterates Buy Rating on Rezolute (rzlt)

May 28, 2025 08:02AM Rezolute Inc. (RZLT) Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

May 14, 2025 04:55PM Rezolute, Inc. (RZLT) Misses Q3 EPS by 3c

May 5, 2025 08:02AM Rezolute (RZLT) Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Apr 23, 2025 08:05AM Rezolute Inc. (RZLT) Announces $90M Share and Warrant Offering at $3.25/sh

Apr 23, 2025 08:04AM Rezolute (RZLT) Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism

Mar 26, 2025 07:31AM Rezolute Inc. (RZLT) Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

Feb 13, 2025 04:14AM Rezolute (RZLT) PT Raised to $9 at JMP Securities

Feb 12, 2025 05:43PM Rezolute, Inc. (RZLT) Tops Q2 EPS by 3c

Feb 5, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on Rezolute (RZLT)

Feb 4, 2025 08:00AM Rezolute Inc. (RZLT) Provides Update on its Phase 3 sunRIZE Study of Ersodetug

Jan 7, 2025 08:02AM Rezolute (RZLT) Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Dec 4, 2024 06:01AM BTIG Reiterates Neutral Rating on Rezolute (RZLT)

Dec 3, 2024 08:00AM Rezolute Inc. (RZLT): FDA Grants Orphan Drug Designation to Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Nov 8, 2024 07:16AM Rezolute, Inc. (RZLT) Tops Q1 EPS by 9c

Sep 27, 2024 06:50AM H.C. Wainwright Reiterates Buy Rating on Rezolute (RZLT)

Sep 20, 2024 11:55AM Jones Trading Reiterates Buy Rating on Rezolute (RZLT)

Sep 20, 2024 05:22AM BTIG Reiterates Buy Rating on Rezolute (RZLT)

Sep 10, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on Rezolute (RZLT)

Sep 9, 2024 11:58AM Rezolute (RZLT) PT Raised to $15 at BTIG

Sep 9, 2024 08:38AM Jones Trading Reiterates Buy Rating on Rezolute (RZLT) following FDA lift of clinical hold on RZ358

Sep 9, 2024 07:30AM Rezolute Inc. (RZLT): FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

Aug 5, 2024 05:02PM Rezolute Inc. (RZLT) Files for 4.5M Share Offering by Selling Stockholders

Aug 5, 2024 07:30AM Rezolute Inc. (RZLT) Announces FDA Clearance of IND Application for Phase 3 Study of RZ358

View Older Stories